Tyrosine News and Research

RSS

The potential of polyunsaturated fatty acids in alleviating depression and reducing suicide risk

Research in 'Molecular Psychiatry' explores the role of long-chain polyunsaturated fatty acids (LC-PUFAs) in major depressive disorder (MDD) and suicide risk, showing mixed results in clinical trials for depression treatment. The study underscores the need for further investigation into LC-PUFAs' neurobiology to advance personalized medicine for mood disorders and suicide prevention.

26 Nov 2023

Exploring the impact of soy isoflavones in prostate cancer therapy

The cellular mechanisms of soy isoflavones, genistein, daidzein, and equol.

23 Nov 2023

Fecal microbiota transplantation boosts survival in metastatic colorectal cancer treatment

A recent study in eClinicalMedicine found that fecal microbiota transplantation, combined with fruquintinib and tislelizumab, significantly improved survival rates in patients with microsatellite stable metastatic colorectal cancer, showing manageable safety and notable increases in progression-free and overall survival.

15 Nov 2023

Breakthrough study: inhibiting USP30 gene offers hope in treating Parkinson’s disease

Whether USP30 inhibition can serve as a disease-modifying therapy for Parkinson's disease (PD).

15 Nov 2023

Novel cancer immunotherapy compound degrades an enzyme found in cancer cells and T cells

Researchers in Purdue University's College of Pharmacy are leveraging the dual roles played by an enzyme found in both cancer cells and T cells to create a novel cancer immunotherapy compound.

14 Nov 2023

Unraveling the role of HER2 mutant alleles in breast cancer

A new editorial paper was published in Oncotarget's Volume 14 on October 31, 2023, entitled, "The uncharted role of HER2 mutant alleles in breast cancer."

6 Nov 2023

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.

6 Nov 2023

Using ripretinib and surgery to manage recurrent gastrointestinal stromal tumor

A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, "Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery."

3 Nov 2023

New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer

The safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib.

2 Nov 2023

New antibody may offer effective drug treatment for breast cancer

An enzyme that may help some breast cancers spread can be stopped with an antibody created in the lab of Cold Spring Harbor Laboratory Professor Nicholas Tonks.

30 Oct 2023

Hormones and high blood pressure: Study reveals endocrine culprits and targeted treatments

Researchers delve into endocrine causes of hypertension (HTN), revealing key culprits like primary aldosteronism and Cushing's syndrome. The study also evaluates the efficacy of various treatments, offering valuable insights for tackling this widespread health issue.

15 Oct 2023

Intracellular journey: The penetration of antidepressants into cells, organelles, and membranes

Researchers in neuropsychopharmacology challenge conventional wisdom about antidepressants' actions, revealing significant intracellular activity that influences their effectiveness. Utilizing advanced technologies, the study prompts a reevaluation of drug targeting and mechanisms, opening new avenues for treating depression.

12 Oct 2023

What are the pharmacological properties of black goji berries?

The pharmacological effects of the components of Lycium ruthenicum Murray fruits.

29 Sep 2023

The power of nanobodies: How they impact COVID-19 immune response

The structures of 340 antibodies (Abs) and 83 nanobodies.

25 Sep 2023

Unlocking the secret soldiers: How dendritic cells could revolutionize cancer immunotherapy

A recent review in the journal Immunity delves into the crucial role of dendritic cells (DCs) in shaping T-cell responses in cancer, highlighting their importance in both priming anti-tumor immunity and in ongoing immune interactions within tumors. The findings underscore the potential of DCs as key targets for next-generation cancer immunotherapies.

18 Sep 2023

A novel multi-epitope vaccine targeting extracellular proteins of Chlamydia pneumoniae

Researchers designed and evaluated a multi-epitope vaccine targeting the main outer membrane protein of Chlamydia pneumoniae using immunoinformatics.

14 Sep 2023

A combination of inhibitors may suppress tumor growth and prevent cancer relapse

An international team of researchers has demonstrated that a combination of inhibitors may suppress tumor growth and prevent relapse in patients with certain cancers, including head and neck squamous cell carcinoma and lung adenocarcinoma.

12 Sep 2023

Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancer

The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.

11 Sep 2023

Can SARS-CoV-2 infect poultry?

New research in the Virology Journal suggests that chickens could become intermediate hosts for newly emerged SARS-CoV-2 variants, posing a potential threat to public health. The study identifies AXL and ACE2 receptors in chickens as likely binding sites for the virus, highlighting the need for further research and preventive measures.

5 Sep 2023

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC).

1 Sep 2023